When is dupixent loe?

I’m not sure what you mean by “LOE.” Do you mean:

- line of therapy (where Dupixent fits in treatment steps), or
- level of evidence for a particular use?

Dupixent (dupilumab) is approved for several conditions, and where it sits in treatment can vary by indication. Here are general ideas about line of therapy (without dosing):

- Atopic dermatitis (eczema) in adults and adolescents 12+: Often used after topical therapies are insufficient or not suitable. It’s a systemic option when disease is moderate-to-severe and not well controlled with topicals, and may be chosen based on disease burden and comorbidities.
- Asthma (moderate-to-severe, eosinophilic or corticosteroid-dependent): Add-on therapy for patients aged 12 and up who remain symptomatic despite standard inhaled therapy; can reduce exacerbations and steroid use.
- Chronic rhinosinusitis with nasal polyps (CRSwNP): For adults not adequately controlled with standard therapy; used as an add-on to improve symptoms.
- Eosinophilic esophagitis (EoE): In some regions, for certain patients not adequately controlled with other therapies; availability varies by country and label.

If you can tell me which condition you’re asking about and what country you’re in (FDA, EMA, etc.), I can give a more precise answer about where Dupixent is recommended in the treatment sequence and what the current approvals say. Also, if you meant something else by LOE, let me know and I’ll tailor the info.